Jashin J Wu1, Corey Pelletier2, Brian Ung2, Marc Tian2, Ibrahim Khilfeh3, Jeffrey R Curtis4. 1. Dermatology Research & Education Foundation, Irvine, CA 92620, USA. 2. US HEOR, Bristol-Myers Squibb, 86 Morris Avenue, Summit, NJ 07901, USA. 3. Global Health Economics, Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA 91320, USA. 4. Department of Medicine, Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, FOT 802D, Faculty Office Tower, Birmingham, AL 35294, USA.
Abstract
Aim: Treatment switching and healthcare costs were compared among biologic-naive psoriasis patients initiating apremilast or biologics with ≥12 months pre-/post-index continuous enrollment in Optum Clinformatics™ Data Mart. Methods: After propensity score matching, switch rates (new therapy post-index) and days between index and switch were assessed. Total and per-patient per-month costs by service type were assessed. Results: Apremilast initiators (n = 533) were matched and compared with biologic initiators (n = 955). Twelve-month cumulative switch rates and days to switch were similar. Apremilast initiators had significantly lower total healthcare costs than biologic initiators; apremilast switchers and nonswitchers had significantly lower per-patient per-month costs than biologic switchers and nonswitchers, driven mainly by reduced outpatient pharmacy costs. Conclusion: Apremilast initiators had lower healthcare costs even with treatment switching.
Aim: Treatment switching and healthcare costs were compared among biologic-naive psoriasispatients initiating apremilast or biologics with ≥12 months pre-/post-index continuous enrollment in Optum Clinformatics™ Data Mart. Methods: After propensity score matching, switch rates (new therapy post-index) and days between index and switch were assessed. Total and per-patient per-month costs by service type were assessed. Results: Apremilast initiators (n = 533) were matched and compared with biologic initiators (n = 955). Twelve-month cumulative switch rates and days to switch were similar. Apremilast initiators had significantly lower total healthcare costs than biologic initiators; apremilast switchers and nonswitchers had significantly lower per-patient per-month costs than biologic switchers and nonswitchers, driven mainly by reduced outpatient pharmacy costs. Conclusion: Apremilast initiators had lower healthcare costs even with treatment switching.
Authors: Andrea Picchianti-Diamanti; Francesca Romana Spinelli; Maria Manuela Rosado; Fabrizio Conti; Bruno Laganà Journal: Int J Mol Sci Date: 2021-03-05 Impact factor: 5.923